A carregar cotações...
Previsão
O preço-alvo médio dos analistas é € 1,98 (-80,68%). A mediana é € 1,82 (-82,24%).
| Comprar |
3 |
| Manter |
13 |
| Vender |
2 |
Discussões na comunidade
- Ticker Symbol neben ISIN und WKN
Hallo zusammen, wenn möglich würde ich gerne parallel zur ISIN und WKN das zugehörige Tickersymbol in der Übersicht zum Wertpapier sehen: Beispiele Aktie Amarin Co. ADR ISIN US0231112063 WKN A0NBNG…
OM Olaf Müller IV em Portfolio Tracking
3 2
Notícias Ir para o feed de notícias
Amarin reports 42% revenue decline after missing prior-year license payment
Amarin reported a 42% decline in net revenues for Q2, mainly due to the absence of a $25m license prepayment from Recordati in the prior-year period. Operating expenses fell 59% to $27m after completing a $70m cost‑reduction initiative. US sales of VASCEPA decreased slightly because of generic competition and net price pressure, partly offset by demand; the company recorded its third consecutive quarter of positive cash flow and expects international growth, stable US sales volumes, positive cash flow and a 10% increase in liquid funds by the end of 2026. » Mais em de.investing.com
Amarin emphasizes cost advantage of VASCEPA after approval of new injectable therapies
Amarin clarifies that VASCEPA remains a treatment option for severe hypertriglyceridemia and reduced triglycerides by a median of 33% versus placebo. About 50% of patients reached levels below 500 mg/dL after 12 weeks. The company highlights that the annual wholesale prices of the new injectable APOC3 therapies are around $40,000, while VASCEPA costs about $4,200 per patient. Amarin also points to over 30 million prescriptions and the cardiovascular approval in combination with statins. » Mais em de.investing.com
Amarin shareholders block share issuances and restrict equity compensation
Amarin shareholders rejected several key proposals, including the renewal of the authorization to issue new shares, an increase in the reserve under the 2020 Stock Incentive Plan, and the issuance of shares without UK pre-emption rights. While the re-election of several board members and the advisory approval of executive pay were passed, they received lower support levels. The board warns this will severely limit the grant of equity-based incentives, make future variable pay primarily cash‑based, and incur additional costs for paper shareholder communications. Shareholders approved the appointment of Ernst & Young as auditor for fiscal year 2026. » Mais em de.investing.com
Amarin increases sales and reduces operating loss through restructuring
Amarin reported a 7.4% increase in total net revenue for Q1 2026 to $45.1 million and, thanks to restructuring measures, cut operating expenses by 31%. The operating loss fell 32.7% to $11.3 million. The company generated positive cash flow for the second consecutive quarter ($6.4 million) and held $308 million in cash at quarter-end. Vascepa prescriptions in the US rose 17%, and the partnership with Recordati contributed to strong revenue growth in Europe. Amarin expects positive full-year cash flow for 2026 and forecasts Q2 EPS of $0.54, but notes risks from generic competition and regulatory hurdles. » Mais em de.investing.com
Amarin to release quarterly results on Feb. 25, 2026
Amarin will release results for the quarter ended Dec. 31, 2025 on Feb. 25, 2026. Three analysts see an average EPS of $0.034 per share, after a loss of -$2.380 in the year-ago quarter. The consensus expects quarterly revenue of $54.6 million (‑11.6% vs. $61.7 million a year earlier). For the fiscal year, three analysts on average forecast a loss of -$0.661 per share and revenue of $222.5 million compared with $228.7 million the prior year. » Mais em finanzen.net
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresDados financeiros da empresa
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 34,92 mi | 17,50% |
| Ganho bruto | 14,29 mi | 24,51% |
| Ganho líquido | 216,3 mil | 103,28% |
| EBITDA | 842,24 mil | 219,08% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 213,04 mi |
Número de ações | 20,68 mi |
Máximo/mínimo de 52 semanas | € 15,76 - € 10,25 |
| Dividendos | Não |
Beta | 0,79 |
PER (PE Ratio) | -10,80 |
PEG (PEG Ratio) | -0,07 |
P/VC (PB Ratio) | 0,53 |
P/V (PS Ratio) | 1,33 |
Perfil da empresa
A Amarin Corporation plc, uma empresa farmacêutica, dedica-se ao desenvolvimento e à comercialização de terapêuticas para o tratamento de doenças cardiovasculares nos Estados Unidos, na Alemanha, no Canadá, no Líbano e nos Emirados Árabes Unidos. O seu produto principal é o VASCEPA, um produto de ácidos gordos ómega-3 de venda exclusivamente sob receita médica, utilizado como complemento à dieta para reduzir os níveis de triglicéridos em doentes adultos com hipertrigliceridemia grave. A empresa vende os seus produtos principalmente a grossistas e a prestadores de serviços de farmácia especializada. Tem uma colaboração com a Mochida Pharmaceutical Co., Ltd. para desenvolver e comercializar medicamentos e indicações baseados no princípio farmacêutico ativo do Vascepa, o ácido ómega-3, e no ácido eicosapentaenoico. A empresa era anteriormente conhecida como Ethical Holdings plc e mudou o seu nome para Amarin Corporation plc em 1999. A Amarin Corporation plc foi constituída em 1989 e tem sede em Dublin, na Irlanda.
| Nome | Amarin Co. ADR |
| CEO | Aaron D. Berg |
| Sede | Dublin,
du Irlanda |
| Site | |
| Setor | Materiais básicos |
| Indústria | Produtos químicos |
| Entrada em bolsa | 01/04/1993 |
| Colaboradores | 80 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | AMRN |
Frankfurt | EH3A.F |
Düsseldorf | EH3A.DU |
München | EH3A.MU |